Evolent Health, Inc. (EVH) Income Statement Analysis

See more : Atlas Corp. (ATCO-PH) Income Statement Analysis – Financial Results

Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.

You may be interested

Evolent Health, Inc. (EVH)

Industry: Medical - Healthcare Information Services

Sector: Healthcare

Website: https://www.evolenthealth.com

About Evolent Health, Inc.

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	1.96B	1.35B	907.96M	1.02B	846.38M	627.06M	434.95M	254.19M	96.88M	0.00	25.67M	8.35M
Cost of Revenue	1.50B	1.04B	657.55M	701.37M	513.06M	327.83M	269.35M	155.18M	57.40M	0.00	30.02M	11.27M
Gross Profit	460.47M	316.58M	250.41M	321.06M	333.32M	299.24M	165.60M	99.01M	39.48M	0.00	-4.35M	-2.93M
Gross Profit Ratio	23.45%	23.42%	27.58%	31.40%	39.38%	47.72%	38.07%	38.95%	40.75%	0.00%	-16.93%	-35.08%
Research & Development	0.00	27.00M	15.50M	15.10M	19.80M	18.20M	17.20M	11.10M	5.80M	0.00	2.00M	0.00
General & Administrative	0.00	0.00	219.50M	310.55M	392.82M	306.31M	205.67M	160.69M	75.29M	0.00	15.60M	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	358.11M	269.27M	219.50M	310.55M	392.82M	306.31M	205.67M	160.69M	75.29M	0.00	15.60M	15.98M
Other Expenses	173.57M	67.20M	60.04M	61.48M	60.91M	109.00K	171.00K	4.00K	7.17M	-25.25M	1.00K	0.00
Operating Expenses	531.68M	336.46M	279.54M	372.03M	453.73M	350.82M	238.04M	177.92M	82.45M	-25.25M	16.81M	16.69M
Cost & Expenses	2.04B	1.37B	937.09M	1.07B	966.79M	678.65M	507.39M	333.09M	139.85M	-25.25M	46.83M	27.96M
Interest Income	5.26M	1.37M	407.00K	3.16M	3.99M	3.44M	1.66M	0.00	0.00	0.00	0.00	18.00K
Interest Expense	54.21M	15.57M	25.43M	28.34M	14.53M	5.48M	3.64M	723.00K	293.00K	0.00	0.00	0.00
Depreciation & Amortization	123.42M	90.25M	60.04M	60.84M	66.64M	44.52M	32.37M	17.22M	7.17M	0.00	1.21M	114.00K
EBITDA	-24.79M	43.75M	55.66M	-241.38M	-245.95M	-4.15M	-40.40M	-220.31M	-31.51M	-25.25M	-20.35M	-19.51M
EBITDA Ratio	-1.26%	0.54%	9.94%	2.31%	-7.73%	-1.32%	-9.20%	38.10%	-464.44%	0.00%	-257.85%	-233.70%
Operating Income	-71.21M	-59.84M	30.25M	-37.88M	-120.41M	-47.48M	-72.84M	-237.42M	-42.97M	-25.25M	-21.16M	-19.62M
Operating Income Ratio	-3.63%	-4.43%	3.33%	-3.71%	-14.23%	-7.57%	-16.75%	-93.40%	-44.36%	0.00%	-82.41%	-235.07%
Total Other Income/Expenses	-131.19M	-65.72M	12.61M	-67.69M	-18.23M	-6.67M	-3.56M	-114.00K	386.26M	-25.25M	41.19M	19.00K
Income Before Tax	-202.41M	-62.08M	-29.80M	-337.80M	-327.12M	-54.15M	-76.40M	-237.53M	343.29M	-25.25M	20.03M	-19.60M
Income Before Tax Ratio	-10.31%	-4.59%	-3.28%	-33.04%	-38.65%	-8.64%	-17.57%	-93.45%	354.35%	0.00%	78.03%	-234.84%
Income Tax Expense	-89.37M	-43.38M	483.00K	-3.55M	-21.54M	40.00K	-6.64M	-10.76M	23.48M	0.00	8.00K	337.00K
Net Income	-113.04M	-18.70M	-30.28M	-334.25M	-305.58M	-52.66M	-60.67M	-159.74M	332.49M	-25.25M	20.02M	-19.26M
Net Income Ratio	-5.76%	-1.38%	-3.34%	-32.69%	-36.10%	-8.40%	-13.95%	-62.84%	343.21%	0.00%	78.00%	-230.81%
EPS	-1.28	-0.20	-0.35	-3.94	-3.71	-0.68	-0.94	-3.55	13.14	-0.66	0.06	-1.13K
EPS Diluted	-1.28	-0.20	-0.35	-3.94	-3.71	-0.68	-0.94	-3.55	6.93	-0.66	0.06	-1.13K
Weighted Avg Shares Out	111.25M	93.70M	86.07M	84.93M	82.36M	77.34M	64.35M	45.00M	25.13M	38.23M	38.23M	17.00K
Weighted Avg Shares Out (Dil)	111.25M	93.70M	86.07M	84.93M	82.36M	77.34M	64.35M	45.03M	46.14M	38.23M	38.23M	17.00K

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

October 2, 2024gurufocus.com

Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05.

Evolent Health: Let The Bidding Begin

August 23, 2024seekingalpha.com

Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up...

Exclusive: Evolent Health in sale talks after inbound interest, sources say

August 22, 2024reuters.com

Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday.

Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say

August 9, 2024zacks.com

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street...

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

August 8, 2024seekingalpha.com

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates

August 8, 2024zacks.com

Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago.

Evolent Announces Second Quarter 2024 Results

August 8, 2024prnewswire.com

Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.

3 Top Tech Stocks Ready for Robust Gains

August 4, 2024investorplace.com

Investors must always balance growth and stability in their portfolios. While employing defensive positions is essential, deploying capital in high-growth sectors like technology can be a formula that accelerates growth.

Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?

July 17, 2024zacks.com

Evolent Health (EVH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 11, 2024prnewswire.com

Company to Participate in Upcoming Conferences WASHINGTON , July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Evolent Health, Inc. (EVH) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories